8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Jan 25, 2023)

Filed January 25, 2023For Securities:ELV

Summary

Elevance Health, Inc. (ELV) filed an 8-K on January 25, 2023, to report its financial results for the fourth quarter and full year ended December 31, 2022. The filing primarily directs investors to a press release (Exhibit 99.1) that contains the detailed financial performance. While the specific figures for the quarter are not directly in the 8-K, the filing signifies the official release of this information, enabling investors to review Elevance Health's recent operational and financial outcomes. Investors should refer to the furnished press release for comprehensive details on revenue, earnings, and any forward-looking statements or guidance provided by the company. This report also includes standard legal disclaimers and forward-looking statements. It's crucial for investors to understand that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into future SEC filings unless explicitly stated. The company also outlines various risks and uncertainties that could affect future performance, covering aspects like healthcare cost trends, regulatory changes, and competitive pressures, which are important considerations for assessing the company's future outlook.

Key Highlights

  • 1Elevance Health released its Q4 and full-year 2022 financial results on January 25, 2023, via an 8-K filing.
  • 2The primary information source for these results is the press release furnished as Exhibit 99.1.
  • 3The filing serves as official notification of the financial results and directs investors to the press release for details.
  • 4Information furnished in the 8-K and press release is not considered 'filed' for Section 18 purposes.
  • 5The report includes standard forward-looking statements and a detailed list of risk factors that could impact future performance.
  • 6Investors are cautioned to refer to the press release for specific financial metrics and guidance.

Frequently Asked Questions

The specific financial results for the quarter ended December 31, 2022, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to that document for comprehensive financial data.

No, the information furnished in Item 2.02 of this 8-K filing and in Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, unless expressly set forth by specific reference in such filings.

The filing lists numerous risks, including trends in healthcare costs and utilization, regulatory changes (federal and state healthcare laws), potential cybersecurity incidents, competitive pressures, risks associated with government programs like Medicare and Medicaid, integration risks from acquisitions, and potential impacts from economic conditions. Investors should consult the press release and the company's other SEC filings for a complete overview of these risks.

This 8-K filing itself does not explicitly provide updated financial guidance. However, the accompanying press release (Exhibit 99.1) typically includes such forward-looking information and guidance. Investors should review the press release for any updated projections or outlook provided by Elevance Health.